Skip to main content
Christoph Correll, MD, Psychiatry, Glen Oaks, NY

Christoph Ulrich Correll MD

Psychiatry•Glen Oaks, NY

Child & Adolescent Psychiatry

Medical Director, Recognition and Prevention (RAP) Program, Department of Psychiatry, The Zucker Hillside Hospital Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research Professor, Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine

Join to view full profile

  • The Zucker Hillside Hospital Dept of Psych75 59 263RD StreetGlen Oaks, NY 11004

  • Phone+1 718-470-4812

Dr. Correll is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Correll's full profileAlready have an account?

Education & Training

  • Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside Hospital
    Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalFellowship, Child and Adolescent Psychiatry, 2001 - 2003
  • Free Univ Berlin- Fac Med
    Free Univ Berlin- Fac MedClass of 1993
  • Long Island Jewish Medical Center
    Long Island Jewish Medical CenterResidency, Psychiatry

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2013 - 2028

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association Between Cardiovascular Risk Factors and Cognitive Impairment in People with Schizophrenia  
    Christoph Correll, MD, JAMA Psychiatry
  • Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared with Management as Usual for Youth with Common Mental Health Problems  
    Christoph Correll, MD, JAMA Psychiatry
  • Impact of Comprehensive Treatment for First Episode Psychosis on Substance Use Outcomes: A Randomized Controlled Trial  
    Corinne Cather, Robert Rosenheck, Christoph U Correll, Psychiatry Research

Authored Content

  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
  • Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020

Press Mentions

  • FDA Approves CAPLYTA® (Lumateperone) sNDA with Robust New Data Supporting Reduced Risk of Relapse in Schizophrenia
    FDA Approves CAPLYTA® (Lumateperone) sNDA with Robust New Data Supporting Reduced Risk of Relapse in SchizophreniaApril 27th, 2026
  • Deep TMS for Schizophrenia?
    Deep TMS for Schizophrenia?January 20th, 2026
  • International Schizophrenia Experts Develop Consensus Criteria for Relapse
    International Schizophrenia Experts Develop Consensus Criteria for RelapseOctober 9th, 2025

Grant Support

  • Project 4 AcisrNational Institute Of Mental Health2010–2012
  • Project 1 AcisrNational Institute Of Mental Health2010–2012
  • Adverse Events Unit (Research Methods Core)National Institute Of Mental Health2010–2012
  • 3/3-Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Institute Of Mental Health2008–2011
  • Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Center For Research Resources2010

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Christoph Correll, Dr. Christoph Correll, MD, Dr. C Correll, Dr. Christoph Ulrich Correll